OncoMatch/Clinical Trials/NCT06246149
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Is NCT06246149 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Tebentafusp for uveal melanoma.
Treatment: Tebentafusp — At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Required: HLA-A A*02:01 positivity
HLA-A*02:01 positivity by local assessment
Disease stage
Required: Stage III (TNM (AJCC8))
Excluded: Stage I, II
High-risk according to either 1) clinical criteria: TNM (AJCC8) stage III or 2) genetic criteria: monosomy 3 or GEP class 2. Patients with stage I and stage II are only eligible if they meet the genetic criterion declared by the site.
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify